Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

The global biopharmaceutical company stated in a California state filing this week it plans to cut 104 jobs at its offices at ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Gilead Sciences, Inc. (GILD) is currently at $89.04, down $3.08 or 3.34% --Would be lowest close since Oct. 31, 2024, when it closed at $88.82 --On pace for largest percent decrease since Feb. 7, 2024 ...